Before undergoing surgery, cancer patients should look for experienced surgeons, get second opinions and ask about the risks and benefits.

by Stephen Ornes

Physicians are legally permitted to prescribe drugs approved for one purpose to be used for another, a practice called off-label prescribing. The rise of targeted therapies and immunotherapies is creating new challenges for navigating off-label options.

by Kate Yandell

The Biden Cancer Initiative Colloquium gathered experts to discuss obstacles preventing access to care at the AACR Annual Meeting.

by Kevin McLaughlin

Healthy Habits

Could a diet that leads to inflammation increase the risk of developing colorectal cancer?

by Lindsey Konkel

Healthy Habits

Exercise is associated with benefits, even for those who fall short of recommended amounts.

by Jane C. Hu

At the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.

by Kate Yandell

At the AACR Annual Meeting 2018, researchers at Google compared the speed and accuracy of human pathologists and computer algorithms in diagnosing and grading cancer.

by Kevin McLaughlin

A trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non”“small cell lung cancer treatment.

by Brad Jones

In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.

by Brad Jones

Forward Look

Talking to doctors about cancer and its treatment often means being bombarded with numbers, from percentages to risk ratios. Yet many people don’t fully comprehend what the numbers mean. As a result, cancer patients may not understand their prognosis, the effect a treatment might have, or their risk for recurrence. Photo © iStock / PeterHermesFurian To […]

by Cameron Walker